Article Text

Download PDFPDF

11 Targeting 11β-HSD1 to promote angiogenesis – consequences for solid tumour growth
  1. Callam Davidson1,
  2. Morwenna Muir2,
  3. Natalie Homer1,
  4. Ruth Andrew1,
  5. Val Brunton2,
  6. Patrick WF Hadoke1,
  7. Brian R Walker1
  1. 1Centre for Cardiovascular Science, The Queen’s Medical Research Institute, Edinburgh, UK
  2. 2Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, Edinburgh, UK


11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1), which generates active glucocorticoids from inactive precursors, is expressed in glucocorticoid target tissues, including the arterial wall. Since active glucocorticoids are anti-angiogenic 11β-HSD1 inhibitors enhance angiogenesis and may have therapeutic potential in ischaemia. However increased angiogenesis may be detrimental in tumours. This investigation tested the hypothesis that 11β-HSD1 inhibition promotes angiogenesis and tumour growth in mouse models of squamous cell carcinoma (SCC) and pancreatic ductal adenocarcinoma (PDA).

Murine tumour cells (1 × 106) were injected subcutaneously into mice (female, 10–12 weeks, FVB/C57Bl6/J) receiving RM-1 diet with, or without (Control), the 11β-HSD1 inhibitor UE2316 (175 mg/kg). Tumour size was measured every 2–3 days for 2–3 weeks. Sections of tumours were stained for vascular markers (CD31, alpha-smooth muscle actin) for quantification of vessel density. Steroid/drug levels were measured in plasma/tissues using liquid chromatography tandem mass spectrometry whilst 11β-HSD1 activity was assayed in tissue homogenates by high performance liquid chromatography. The effects of 11β-HSD1 inhibition on angiogenesis were examined ex vivo using an aortic ring assay. Data are mean±SEM.

11β-HSD1 inhibition increased SCC tumour growth in FVB mice (p<0.01) but did not affect the growth of PDA tumours in C57Bl6/J mice. Vessel density was unaffected in both tumour types. SCC tumours expressed more 11β-HSD1 mRNA and had higher (p<0.001) enzyme activity (0.291±0.054 nmoles product/mg/min) than PDA tumours (0.038±0.006). FVB mice had higher plasma UE2316 levels than C57Bl6/J mice (164.6±78.28 nM vs 14.4±6.23 nM), and reduced circulating corticosterone after UE2316 treatment. UE2316 reduced type 1 collagen in SCC tumours (9.8±0.8 vs 3.8%±0.6% area, p<0.001). Pharmacological inhibition of 11β-HSD1 did not alter steroid-mediated angiostasis in aortic rings.

11β-HSD1 inhibition does not promote angiogenesis in SCC or PDA tumours, but may increase SCC growth through a mechanism involving reduced fibrosis. Whether 11β-HSD1 inhibition increases angiogenesis in glucocorticoid-sensitive tumours remains to be established.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.